SGLT2 Inhibitors Monitoring Bundle: Complete Prescriber Reference

What Is the SGLT2 Inhibitor Drug Class?

SGLT2 inhibitors block the sodium-glucose cotransporter-2 protein in the proximal renal tubule, preventing reabsorption of roughly 90% of filtered glucose. The result is glycosuria of 60 to 80 grams per day independent of insulin secretion. That mechanism also drives modest osmotic diuresis, a 3 to 5 mmHg reduction in systolic blood pressure, and a 2 to 3 kg weight reduction over 26 weeks in clinical trials. The FDA first approved canagliflozin in March 2013.

The Four Approved Agents and Their Approved Indications

Four agents hold FDA approval as of mid-2025:

| Agent | Brand | T2DM | HFrEF/HFpEF | CKD | |---|---|---|---|---| | Empagliflozin | Jardiance | Yes | Yes | Yes | | Dapagliflozin | Farxiga | Yes | Yes | Yes | | Canagliflozin | Invokana | Yes | No | Yes (CREDENCE) | | Ertugliflozin | Steglatro | Yes | No | No |

Empagliflozin and dapagliflozin carry the broadest label reach. Ertugliflozin currently has glycemic labeling only; its VERTIS CV trial showed non-inferiority for MACE but did not demonstrate superiority on the secondary heart failure endpoint. See the VERTIS CV primary publication in NEJM (2020).

Mechanism Driving Non-Glycemic Benefits

Beyond glucosuria, two additional mechanisms appear to explain cardiovascular and renal protection. First, reduced tubuloglomerular feedback from lower distal sodium delivery causes afferent arteriolar constriction, reducing intraglomerular pressure. Second, these agents shift myocardial metabolism from glucose toward ketone bodies, a more oxygen-efficient fuel. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo in patients with established atherosclerotic cardiovascular disease and type 2 diabetes. DAPA-HF (N=4,744) then confirmed dapagliflozin 10 mg reduced worsening heart failure or CV death by 26% in patients with HFrEF regardless of diabetes status.

Baseline Assessment Before Starting an SGLT2 Inhibitor

Every patient needs a structured pre-treatment evaluation. Labs done at baseline serve two purposes: confirming that eGFR allows glycemic efficacy and ruling out conditions that raise DKA or infection risk.

Required Baseline Labs

• Serum creatinine and eGFR (CKD-EPI 2021 equation): eGFR drives prescribing decisions more than any other value. The 2022 KDIGO CKD guideline recommends SGLT2 inhibitor initiation down to eGFR 20 mL/min/1.73m² for cardiorenal indications, but glycemic efficacy essentially disappears below eGFR 45.
• Urinalysis with microscopy: Active urinary tract infection is a relative contraindication at initiation.
• HbA1c: Establish glycemic baseline; also needed to confirm type 2 vs. Type 1 diabetes (DKA risk is substantially higher in T1DM, these agents are not FDA-approved for T1DM).
• Basic metabolic panel: Baseline potassium matters in patients co-prescribed ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists, given the modest natriuretic effect.
• Blood pressure and weight: Osmotic diuresis can lower BP by 3 to 5 mmHg, clinically meaningful in patients on three or more antihypertensives.

Clinical Risk Stratification Before Starting

The 2023 ADA Standards of Care, Section 9 state that patients with eGFR <45 mL/min/1.73m² should not expect significant HbA1c lowering from this class. For those patients, the renal and cardiac benefit, not glycemic control, is the indication. Clarifying which benefit you are prescribing for determines how you counsel the patient and how you define success.

Patients with a history of recurrent genital mycotic infections, low-carbohydrate or ketogenic diets, alcohol use disorder, or insulin-deficient states (including latent autoimmune diabetes in adults, LADA) carry elevated euglycemic DKA risk and require explicit counseling before prescription.

The Ongoing Monitoring Bundle

Monitoring does not end after the prescription is written. The following schedule is consistent with the 2023 ADA Standards, the 2022 ACC/AHA/HFSA Heart Failure Guideline, and KDIGO 2022.

Monitoring Schedule Table

| Timepoint | Tests | Action Thresholds | |---|---|---| | Baseline | eGFR, BMP, HbA1c, UA | Hold if eGFR <20 (cardiorenal) or <45 (glycemic-only indication) | | 2 to 4 weeks | BP, symptoms of volume depletion, genital symptoms | Reduce diuretics if orthostatic; treat mycotic infection | | 3 months | eGFR, HbA1c, weight | If eGFR falls >30% from baseline, reassess cause | | 6 months | eGFR, BMP, HbA1c, foot exam (canagliflozin) | Canagliflozin: reassess amputation risk factors | | Annually | eGFR, BMP, HbA1c, UACR, weight, BP | Adjust dose tier if eGFR crosses threshold |

eGFR Trajectory Monitoring

A short-term eGFR dip of up to 10% in the first 2 to 4 weeks is expected and reflects reduced intraglomerular pressure, not true nephron loss. The CREDENCE trial (N=4,401) showed canagliflozin reduced the composite of end-stage kidney disease, doubling of serum creatinine, or renal/CV death by 30% despite an early eGFR dip. Do not stop the drug for a small, stable dip.

Stop or hold if:

• eGFR falls more than 30% from baseline within 4 weeks (investigate volume depletion, NSAID use, contrast exposure)
• eGFR drops below 20 mL/min/1.73m² persistently
• Patient progresses to dialysis or receives a kidney transplant

Volume Status and Blood Pressure

Osmotic diuresis from glucosuria adds to the diuretic burden of loop diuretics or thiazides. Review the patient's diuretic dose at the first follow-up visit, typically 2 to 4 weeks. The DAPA-HF investigators allowed down-titration of background diuretics during the trial, which is appropriate clinical practice. Symptomatic orthostasis warrants loop diuretic dose reduction before stopping the SGLT2 inhibitor.

Infection Surveillance

Genital mycotic infections occur in roughly 10 to 15% of women and 4 to 5% of men on SGLT2 inhibitors, the mechanism is glucosuria-driven vaginal or periurethral yeast colonization. Most respond to a single dose of fluconazole 150 mg or topical azole. Recurrent infections (three or more episodes per year) may necessitate stopping the drug. FDA's 2013 prescribing information for canagliflozin flagged this risk at approval.

Fournier gangrene (necrotizing fasciitis of the perineum) is rare but life-threatening. The FDA added a black box warning in 2018 after 12 post-marketing cases. Instruct every patient to report perineal pain, swelling, or fever immediately.

DKA Risk: Recognition and Prevention

Euglycemic diabetic ketoacidosis is the most under-recognized serious adverse event associated with this class. Blood glucose may be only 150 to 200 mg/dL at presentation, so the diagnosis is missed unless the clinician has a high index of suspicion. The FDA issued a safety communication in May 2015 reporting 20 cases, subsequently expanded as pharmacovigilance data accumulated.

Who Is at Highest DKA Risk

• Type 1 diabetes or LADA (use off-label; risk is substantially elevated)
• Patients on very-low-carbohydrate or ketogenic diets
• Heavy alcohol use
• Insulin dose reductions without provider guidance
• Perioperative fasting states

The Perioperative Hold Protocol

Hold SGLT2 inhibitors 3 days before elective surgery requiring general anesthesia or prolonged NPO status; hold 4 days before major abdominal, thoracic, or cardiac procedures. This recommendation appears in the 2023 ADA Standards of Care, Section 16 (Diabetes Care in the Hospital) and the Society for Ambulatory Anesthesia (SAMBA) 2023 consensus statement.

Restart only after the patient is eating normally and ketone testing is negative if available.

DKA Screening in Symptomatic Patients

Any patient on an SGLT2 inhibitor who presents with nausea, vomiting, abdominal pain, or malaise should have a point-of-care blood or urine ketone test regardless of glucose level. A venous blood gas with bicarbonate below 18 mEq/L in this setting should trigger full DKA workup.

Dose Selection and Adjustment by Indication

Dose selection depends on the approved indication, not just on eGFR alone.

Empagliflozin Dosing

• T2DM: Start 10 mg once daily; may increase to 25 mg once daily for additional glycemic effect.
• HF (HFrEF or HFpEF): 10 mg once daily regardless of diabetes status. The EMPEROR-Preserved trial (N=5,988) showed empagliflozin 10 mg reduced CV death or HF hospitalization by 21% in HFpEF.
• CKD: 10 mg once daily; can initiate down to eGFR 20 per the 2023 FDA label update.

Dapagliflozin Dosing

• T2DM: 5 mg or 10 mg once daily.
• HF: 10 mg once daily. The DAPA-HF trial used 10 mg exclusively.
• CKD (UACR >200 mg/g or eGFR 25 to 75): 10 mg once daily per DAPA-CKD (N=4,304), which showed a 39% reduction in the primary composite kidney outcome.

Canagliflozin Dosing

• T2DM: 100 mg once daily before first meal; may increase to 300 mg.
• CKD (CREDENCE): 100 mg once daily. Do not titrate to 300 mg in CKD, the CREDENCE trial used 100 mg.
• Amputation risk: The CANVAS trial identified a 2-fold increase in lower-limb amputation risk (6.3 vs. 3.4 per 1,000 patient-years). Reassess at every visit in patients with peripheral artery disease, prior amputation, or active foot ulcers.

Drug Interactions and Comorbidity Adjustments

Diuretics and Volume Depletion

Combining SGLT2 inhibitors with loop diuretics increases the risk of volume depletion. In HF patients, the EMPEROR-Reduced investigators found that empagliflozin allowed stable or reduced loop diuretic doses over 52 weeks, a favorable interaction. Still, monitor BUN, creatinine, and orthostatic blood pressure at 2 to 4 weeks after starting.

ACE Inhibitors, ARBs, and MRAs

Combining SGLT2 inhibitors with renin-angiotensin-aldosterone system (RAAS) blockers is standard practice in CKD and HF. The combination is generally safe. The small natriuretic effect of SGLT2 inhibitors may modestly raise potassium in patients already on dual RAAS blockade, check potassium at 4 weeks if adding an SGLT2 inhibitor to an ACE inhibitor plus spironolactone regimen.

Insulin and Sulfonylureas

SGLT2 inhibitors added to insulin or sulfonylureas increase hypoglycemia risk through additive glucose lowering. Reduce sulfonylurea dose by 50% at initiation and reduce basal insulin by 20% when starting an SGLT2 inhibitor in patients on insulin. The 2023 ADA Standards, Section 9 specifically note this interaction.

Special Populations

Patients With CKD Stage 3b, 4

The expansion of SGLT2 inhibitor use into CKD stages 3b and 4 is one of the most significant label changes in recent nephrology practice. KDIGO 2022 states:

"We recommend treating patients with type 2 diabetes, CKD, and eGFR >=20 mL/min/1.73 m² with an SGLT2 inhibitor." (KDIGO 2022 CKD Guideline, Chapter 4)

The glycemic benefit is minimal at eGFR <45, but the cardiorenal benefit persists down to eGFR 20. Counsel patients at this eGFR range that the goal is kidney and heart protection, not HbA1c reduction.

Older Adults (Age 65 and Above)

Volume depletion risk increases with age. A retrospective cohort analysis using Medicare data (Fralick et al., BMJ 2017) found that SGLT2 inhibitors did not increase fracture risk overall, but canagliflozin carries an FDA warning for bone density reduction and fracture risk, check baseline bone density in older women before prescribing canagliflozin specifically. Use empagliflozin or dapagliflozin preferentially in patients with osteoporosis.

Pregnancy and Lactation

SGLT2 inhibitors are contraindicated in the second and third trimesters due to fetal renal toxicity. The FDA labeling for empagliflozin states that animal studies showed kidney malformation at organogenesis-equivalent exposures. Stop the drug as soon as pregnancy is confirmed.

Stopping Rules and Dose Interruption Criteria

A clear stopping protocol reduces the risk of serious harm.

Stop immediately and do not restart without reassessment:

• Confirmed DKA (any glucose level with elevated ketones and metabolic acidosis)
• Fournier gangrene
• eGFR below 20 mL/min/1.73m² on two measurements 4 weeks apart
• Progression to renal replacement therapy
• Confirmed pregnancy (second or third trimester)

Hold temporarily:

• Major surgery or general anesthesia (hold 3 to 4 days before; restart when eating)
• Prolonged illness with poor oral intake (sick-day rule)
• Contrast nephropathy risk (hold day of contrast; restart 48 hours after if eGFR stable)
• Active serious infection (sepsis, pyelonephritis)

The sick-day rule deserves explicit patient education: any illness causing reduced oral intake, vomiting, or diarrhea lasting more than 24 hours should prompt a drug hold. Patients do not intuitively know that a drug affecting kidney glucose handling can cause DKA during fasting. Written sick-day instructions, given at the time of prescribing, reduce this risk. A 2021 consensus statement from the UK's Joint British Diabetes Societies formalizes sick-day guidance for SGLT2 inhibitors and is reproducible for patient handouts.

Patient Counseling Checklist

Effective prescribing includes a structured counseling visit. At minimum, cover these points:

1. Genital hygiene: Daily washing of the genital area reduces mycotic infection risk. Women should wipe front to back. Report any itching, discharge, or odor.
2. Hydration: Drink at least 6 to 8 glasses of water per day, especially in hot weather or during exercise.
3. Sick-day rule: Hold the medication and contact the practice if unable to eat or drink for more than 24 hours.
4. Perioperative hold: Tell every surgeon, anesthesiologist, and emergency provider that you take this drug.
5. Perineal warning: Any perineal pain, swelling, or redness is an emergency. Go to the ER.
6. Glucosuria on dipstick: The drug intentionally causes glucose in the urine, a positive urine dipstick glucose does not mean the medication is failing.
7. Shoe and foot checks (canagliflozin patients): Inspect feet daily; report any new sores, pain, or discoloration.

Summary of Key Trial Data Cited in This Article

| Trial | N | Agent | Primary Outcome | Result | |---|---|---|---|---| | EMPA-REG OUTCOME | 7,020 | Empagliflozin 10/25 mg | 3-point MACE | 14% RRR; CV death 38% RRR | | DAPA-HF | 4,744 | Dapagliflozin 10 mg | Worsening HF or CV death | 26% RRR | | EMPEROR-Preserved | 5,988 | Empagliflozin 10 mg | CV death or HF hospitalization | 21% RRR | | EMPEROR-Reduced | 3,730 | Empagliflozin 10 mg | CV death or HF hospitalization | 25% RRR | | CREDENCE | 4,401 | Canagliflozin 100 mg | ESKD, 2x Cr, renal/CV death | 30% RRR | | DAPA-CKD | 4,304 | Dapagliflozin 10 mg | Sustained eGFR decline, ESKD, death | 39% RRR | | CANVAS | 10,142 | Canagliflozin 100/300 mg | 3-point MACE | 14% RRR; amputation risk 2x | | VERTIS CV | 8,246 | Ertugliflozin 5/15 mg | 3-point MACE | Non-inferior; no HF superiority |